Astrazeneca Ab

Michael Howard Block

Roger John Butlin

Thorsten Nowak

Jeremy Nicholas Burrows

Craig Johnstone

Kevin Michael Foote

Roger James

Clifford David Jones

Janet Elizabeth Pease

Rodney Brian Hargreaves

Suzanne Saxon Bowker

Scott Boyd

Peter William Rodney Caulkett

Darren McKerrecher

David R Brittain

Sandra Ann Filla

Darren Mckerrecher

Xiaolan Zheng

Maria-Elena Theoclitou

Craig Samuel Donald

Wayne Brailsford

Audrey Davies

Brian Aquila

Timothy Pontz

David Stephen Clarke

Jayachandran Ezhuthachan

Daniel John Russell

The invention relates to the use of a compound of Formula (I) or a salt, solvate or prodrug thereof, wherein R, R, R, n and m are as described in the specification, in the preparation of a medicament for the treatment or prevention of a disease condition mediated through glucokinase (GLK), such as type 2 diabetes. The invention also relates to a novel group of compounds of Formula (I) and to methods for preparing compounds of Formula (I).

Compounds effecting glucokinase

The invention relates to the use of a compound of Formula (I) or a salt, solvate or prodrug thereof, wherein R, R, R, n and m are as described in the specification, in the preparation of a medicament for the treatment or prevention of a disease condition mediated through glucokinase (GLK), such as type 2 diabetes.  The invention also relates to a novel group of compounds of Formula (I) and to methods for preparing compounds of Formula (I).

This invention relates to novel compounds having the structural formula (I) and to their pharmaceutical compositions and to their methods of use. These novel compounds provide a treatment or prophylaxis of cancer.

Enantiomers of selected fused heterocyclics and uses thereof

The use of a compound of formula (I) in the manufacture of a medicament for the treatment, in a warm-blooded animal, of disorders mediated by the neuropeptide Y5 receptor: wherein: Pharmaceutical compositions, methods and processes for preparation of compounds of formula (I) are also described.

Carbazole derivatives and their use as NPY5 receptor antagonists

Compounds of formula (I): wherein: and R, R, R, n, x, y and z are as defined within are described. Processes for their preparation and their use in the treatment of disorders mediated by the neuropeptide Y5 receptor in a warm-blooded animal, such as a human being, are also described.

Amino substituted dibenzothiophene derivatives for the treatment of disorders mediated by NP Y5 receptor

Compounds of formula (I):wherein: Processes for their preparation and their use in the treatment of disorders mediated by the neuropeptide Y5 receptor in a warm-blooded animal, such as a human being are also described.

The use of compounds of formula (I), and salts thereof; and pharmaceutically acceptable in vivo cleavable prodrugs of said compound of formula (I); and pharmaceutically acceptable salts of said compound or said prodrugs; in formula (I), Ring C is phenyl or a carbon linked heteroaryl ring substituted as defined within; Ris an ortho substituent as defined within; n is 1 or 2; A-B is a linking group as defined within; Rand Rare as defined within; Ris hydroxy, hydrogen, halo, amino or methyl; in the manufacture of a medicament for use in the elevation of PDH activity in warm-blooded animals such as humans is described. Pharmaceutical compositions, methods and processes for preparation of compounds of formula (I) are also described

Use of compounds for the elevation of pyruvate dehydrogenase activity

Amides as inhibitors for pyruvate dehydrogenase

A compound of formula (I) wherein: n is 1 or 2; R is chloro, fluoro, bromo, methyl or methoxy; R is as defined within; R is as defined within; and R is hydrogen or fluoro; or a pharmaceutically acceptable salt or an in vivo hydrolysable ester thereof is described. The use of compounds of formula (I) in the production of an elevation of PDH activity in a warm-blooded animal such as a human being are also described. Pharmaceutical compositions, methods and processes for preparation of compounds of formula (I) are detailed.

Substituted N-phenyl 2-hydroxy-2-methyl-3,3,3-trifluoropropanamide derivatives which elevate pyruvate dehydrogenase activity

A compound of formula (I) wherein: R , R , R , R , R , R and R are as defined within; or a pharmaceutically acceptable salt or an in vivo hydrolysable ester thereof is described. The use of compounds of formula (I) in the production of an elevation of PDH activity in a warm-blooded animal such as a human being are also described. Pharmaceutical compositions, methods and processes for preparation of compounds of formula (I) are detailed.

Chemical compounds

Growing community of inventors

Waltham, MA, United States of America

Michael Howard Block